Sun Pharma got a start in Japan when it paid Novartis nearly $300 million a couple of years ago for more than a dozen drugs the Swiss drugmaker was unloading.
A Chinese maker of heparin, APIs and some finished drugs is launching the second phase of its manufacturing plant, investing nearly $150 million as it moves into producing innovative biologic drugs for the Chinese market.
Just months after announcing a $65 million expansion that will boost capacity at the North Carolina facility where it makes diabetes medications, Novo Nordisk says it needs yet more...